Tetrahydrobiopterin deficiencies

PTC Therapeutics to Acquire Censa Pharmaceuticals, Developer of an Experimental Phenylketonuria Drug
source: pixabay.com

PTC Therapeutics to Acquire Censa Pharmaceuticals, Developer of an Experimental Phenylketonuria Drug

According to a story from Xconomy, the drug company PTC Therapeutics has come to an agreement that will allow it to acquire Censa Pharmaceuticals and its lead product candidate. This…

Continue Reading PTC Therapeutics to Acquire Censa Pharmaceuticals, Developer of an Experimental Phenylketonuria Drug
We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.
Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Partner With Us
Submit a Story
Become a Contributor

Keep Up to Date

Subscribe to Our Newsletter
Check Out Rare Events
Get Inspired By Our Memes

Learn More

About Us
Rare Diseases and Conditions
Terms of Use
Privacy Policy

© Copyright Patient Worthy